GLP-1 drugs and body acceptance: what the science says

What did @olasingsss actually say?

The video is raw and relatable, not a medical claim. @olasingsss stepped on a scale, saw 95 kg after previously being 92 kg, and had what looked like a genuine moment of frustration. They said "I can't do this anymore" and appeared to reference Ozempic, though the transcript is garbled enough that the exact framing is unclear. The clearest signal is emotional: a person struggling with weight management who expected different results.

To be fair to the creator, they weren't presenting themselves as an expert. There's no dosage advice, no before-and-after sell, no claims that Ozempic is a miracle drug. This is a person venting about a 3 kg gain while apparently on, or considering, a GLP-1 medication. That context matters enormously for evaluating what's actually being communicated here.

Does the science back this up?

Weight gain while on a GLP-1 receptor agonist like semaglutide is not common in clinical trials, but it's not impossible either, especially early in treatment or if the medication hasn't reached a therapeutic dose yet. The 3 kg gain here is worth examining, not dismissing.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed average weight loss of about 14.9% body weight with semaglutide 2.4 mg over 68 weeks, but that average hides real variation. Some participants lost very little. Some gained in the first few weeks before losses appeared. A 2022 analysis in Obesity (Rubino et al.) confirmed that non-responders do exist, estimated at roughly 10-15% of patients depending on the threshold used. And critically, weight fluctuates daily due to water retention, hormonal shifts, food timing, and muscle gain from exercise, especially if someone is also going to the gym, as the hashtags suggest.

So a 3 kg increase on the scale doesn't automatically mean the medication isn't working. It might mean it's too early to judge, the dose is still being titrated, or the number reflects water weight rather than fat mass.

What did they get wrong (or right)?

They got the frustration right. Weight loss is not linear and the expectation that a GLP-1 medication produces steady, consistent downward movement on the scale is one of the most common misconceptions clinicians deal with. GLP-1 agonists are not magic number reducers week by week.

What's potentially misleading, not through malice but through implication, is the framing of "I can't do this anymore" after seeing a scale number. If viewers interpret this as evidence that Ozempic doesn't work or causes weight gain, that would be inaccurate. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) on tirzepatide showed average reductions of up to 22.5% body weight, but also showed that early weeks can involve minimal change or even slight increases.

The creator didn't make explicit medical claims, so there's not much to fact-check in the clinical sense. But the emotional framing carries weight of its own in a 136K-view video, and that's worth naming.

What should you actually know?

If you're on a GLP-1 medication and the scale went up, here's what the evidence actually says before you spiral.

• Scale weight is not the same as fat mass. Water retention, muscle gain from resistance training (which the gym hashtag suggests is relevant here), and food volume in the gut can add 2-4 kg without any meaningful change in body composition.
• GLP-1 medications typically require dose escalation over 16-20 weeks before reaching the full therapeutic dose. Weight loss in early phases is often minimal.
• Non-response is real. A 2023 paper in eClinicalMedicine (Aroda et al.) noted that patients should be assessed at 16 weeks to determine whether they're responding, not at 4 or 8 weeks.
• "I can't do this anymore" is a valid emotional response to a frustrating scale reading. It's not clinical evidence of anything.
• If you're concerned about weight changes on a GLP-1 medication, talk to a licensed prescriber before stopping or changing anything. Scale fluctuations in the first weeks are normal and expected.

The bigger picture on GLP-1 frustration content

Videos like this one spread because they're real. They're not pharma ads and they're not diet culture. They're people wrestling with bodies that don't respond the way they expected. That authenticity is valuable. But 136,000 views means 136,000 people who might walk away thinking Ozempic made someone gain weight, without any of the clinical context above.

GLP-1 medications are serious, regulated treatments. They work for most people over time. They don't work for everyone. And the scale in week three or four is a terrible way to measure either of those things.